Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin have announced that full data from the pivotal KOMET-001 trial of their investigational menin inhibitor, ziftomenib, will be presented at the 2025 ...
Kura Oncology's ziftomenib shows promise in AML treatment, with key data readouts expected in 2025, but faces competition from Syndax's revumenib. Kura's strong cash position supports operations ...
Kura Oncology, Inc. (NASDAQ:KURA) is one of the Top 10 Stocks Under $10 That Could Triple. On September 1, TipRanks reported that Charles Zhu from LifeSci Capital reiterated a Buy rating on Kura ...
Twice to hold eight listening parties, one chat session for new album 'This Is For' Twice to drop Japanese single 'Kura Kura' on May 12 Girl group Twice to drop new single on Dec. 18 Twice to release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback